A Randomized, Double-blind, Multicenter Study Assessing Short and Long-term Efficacy, Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis
收藏DataCite Commons2025-12-16 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012346/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
提供机构：
Vivli
创建时间：
2025-12-16
